HIGHLIGHTS
- What: The authors sought to demonstrate the oncogenic role of SRD5A3 and its interplay with IGF2BP3 via a m6Adependent manner in bladder cancer and CDDP resistance.
- Who: Kai Liao from the Department of Radiotherapy, Guangzhou Institute of Cancer Research, The Affiliated Cancer Hospital, Guangzhou Medical University, No, Hengzhigang, Yuexiu District, Guangzhou, China have published the research work: N6-methyladenosine-modified SRD5A3, identified by IGF2BP3, sustains cisplatin resistance in bladder cancer, in the Journal: (JOURNAL)
- How: Characterization of SRD5A3 in bladder cancer First the GSE231835 dataset was analyzed to identify differentially expressed genes in . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.